



Kateifides Andreas, PhD



HBA-USA Election
Board of Directors 2025-2027

Professional profile (Expertise, degrees, current position, previous positions)

Expertise

Clinical research professional who has supported medical monitoring activities for phase I/II/III trials MD, Ph.D. scientist with a background in IgA Nephropathy, APOL1-Mediated Kidney Disease, non-opioid analgesics, and lipidology.

Degrees

Boston University Graduate School of Management	Boston, MA
<i>MBA, Concentration in Health Sector Management, Business Strategy and Finance</i>	May 2013
Faculty of Medicine, University of Crete	Iraklion, Greece
<i>Ph.D., Molecular Medicine</i>	July 2011
<i>Master of Science, Molecular Medicine</i>	April 2008
<i>Degree of Medicine</i>	July 2005

Current and Previous Positions

Alexion Rare Disease Unit AstraZeneca	2022 – Present; Boston, MA
<i>Senior Medical Director, Clinical Development Sciences</i>	06/2024 – Present
<i>Medical Director, Clinical Development Sciences</i>	08/2022 – 05/2022
Vertex Pharmaceuticals, Inc.	2012 – 2022; Boston, MA
<i>Clinical Scientist Principal, Clinical Science and Site Advocacy</i>	02/2020 – 07/2022
<i>Sr. Clinical Scientist, Clinical Development Support & Site Advocacy</i>	07/2018 – 02/2020
<i>Sr. Business Operations Analyst, Process Management and Business Analytics</i>	07/2017 – 07/2018
<i>Manager, Process Management and Business Analytics</i>	08/2015 – 07/2017
<i>Manager, Compliance Oversight Systems, within CDE and GMDA</i>	03/2014 – 08/2015
<i>Sr. Associate, Clinical Development Execution, Contractor</i>	06/2013 – 01/2014
<i>Clinical Trial Associate, Clinical Compliance and Risk Management, Contractor</i>	07/2012 – 04/2013
Whitaker Cardiovascular Institute, Boston University, School of Medicine	Boston, MA
<i>Research Associate/Graduate Student</i>	10/2006 – 05/2011
Microbiology Lab, Pagnh University Hospital	Iraklion, Greece
<i>Medical Student / Research Assistant</i>	09/2004 – 12/2004

Scientific profile (Research interests, publication record, distinctions & awards)

Promote operational excellence in the execution of clinical trials.
APOL1-mediated kidney diseases and pain management
IgA Nephropathy, Complement inhibition

Priorities regarding activities that the HBA-USA should undertake

- Promote the activities of the Alumni Association of the Student Exchange Program (AASEP)
- Build processes and organize the activities of this program to ensure a database is developed and it is defined how new students can participate in the UoC-BU exchange program.
- Support the financial activities of HBA-USA and AASEP (tax filing, agent filing, subscriptions)

Time commitment that the candidate can take during his term as a BD member:

Less than 4 hours/month ___
 4-10 hours/month X
 10-20 hours/month ___
 More than 20 hours/month ___

Highest position that the candidate would prefer to hold in the BD (more than one can be selected):

President ___
 Vice-President ___
 General Secretary ___
 Treasurer X
 Appointed Secretary ___
 Councilor X
 Any of the above ___

Additional comments that the Candidate wants to make:

Andreas was introduced to HBA-USA in 2011 and from 2017-2019 served as Councilor and since 2019 is the Treasurer of HBA-USA.
 During the second term Andreas worked with Dr. Zannis to establish AASEP under the umbrella of HBA-USA.
 As treasurer Andreas worked with the assistant treasurer to update the process for registering new members and managing donations.